Strides Pharma successfully completes EU GMP inspection of Puducherry facility
Bengaluru: Strides Pharma Science Limited today announced the successful completion of the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungry at its Puducherry facility on April 28, 2021.
"The Company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection," Strides Pharma Science said in a release.
As per the company, the Puducherry facility caters to the U.S., Other Regulated Markets and Institutional businesses and has capabilities to produce finished dosage formulation products across multiple dosage formats.
Commenting on the development, Dr. R. Ananthanarayanan, Managing Director & CEO, remarked "We are pleased with the positive outcome of the recent EU GMP inspection at our Puducherry facility. The positive result of this inspection underscores our commitment to regulatory excellence at our global manufacturing sites. We stay focused on getting the facility reclassified with the USFDA"
The company in August 2020 had also announced successful completion of the UK MHRA inspection at the site.
Read also: Strides Pharma, Ennaid Therapeutics partner to produce life saving oral covid tablet
Strides is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets.
The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida).
